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Abstract: Nanosized metal-organic frameworks (nanoMOFs) MIL-100(Fe) are highly porous and
biodegradable materials that have emerged as promising drug nanocarriers. A challenging issue
concerns their surface functionalization in order to evade the immune system and to provide molecular
recognition ability, so that they can be used for specific targeting. A convenient method for their
coating with tetraethylene glycol, polyethylene glycol, and mannose residues is reported herein.
The method consists of the organic solvent-free self-assembly on the nanoMOFs of building blocks
based on β-cyclodextrin facially derivatized with the referred functional moieties, and multiple
phosphate groups to anchor to the nanoparticles’ surface. The coating of nanoMOFs with cyclodextrin
phosphate without further functional groups led to a significant decrease of macrophage uptake,
slightly improved by polyethylene glycol or mannose-containing cyclodextrin phosphate coating.
More notably, nanoMOFs modified with tetraethylene glycol-containing cyclodextrin phosphate
displayed the most efficient “stealth” effect. Mannose-coated nanoMOFs displayed a remarkably
enhanced binding affinity towards a specific mannose receptor, such as Concanavalin A, due to the
multivalent display of the monosaccharide, as well as reduced macrophage internalization. Coating
with tetraethylente glycol of nanoMOFs after loading with doxorubicin is also described. Therefore,
phosphorylated cyclodextrins offer a versatile platform to coat nanoMOFs in an organic solvent-free,
one step manner, providing them with new biorecognition and/or “stealth” properties.
Keywords: metal-organic frameworks; MIL-100(Fe); β-cyclodextrin; mannose; molecular recognition;
“stealth” effect; multivalent effect; isothermal titration calorimetry; macrophage
1. Introduction
Metal-organic frameworks (MOFs) are currently among the most versatile materials, with
crystalline porous structures built using organic linkers and metal cations. Since they were
discovered [1], their applications were focused on biosensing, gas storage, separation, heterogeneous
catalysis, and imaging [2–8]. More recently, their innovative biomedical applications as potential drug
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delivery nanocarriers are gaining increasing interest for the treatment of a variety of diseases [9–12].
These materials allow tuning pore sizes and shapes by varying both metal cations and organic linkers,
and thus drug interactions with the matrix can be optimized [13]. The opportunity to confer ad hoc
chemical and structural features in addition to the peculiar properties of the internal porous volume
make MOFs promising drug delivery systems (DDS) for a large variety of guest molecules [14].
Among the large MOFs family, nanosized metal-organic frameworks MIL-100(Fe) (MIL standing
for materials of Institute Lavoisier) are a biodegradable material easily synthesized by a “green”
microwave assisted hydrothermal method, made of spontaneous coordination between iron(III) cations
and trimesate linkers (1,3,5-benzene tricarboxylate) generating a porous architecture. The structure
is accessible through mesoporous windows of two different sizes (5.6 and 8.6 Å), and forms internal
cages of 24 and 29 Å available for drug incorporation [15]. MIL-100(Fe) nanoMOFs could entrap a
wide range of therapeutic molecules providing high loadings up to 20–70 wt% [9], and were well
tolerated in vivo in rats since doses up to 220 mg Kg−1 did not trigger any toxicity signs up to one
week after injection [11,12,16]. Although iron concentration increased in both liver and spleen upon
administration, levels remained far from those able to cause liver malfunction, and iron excess was
excreted by urine and feces after 15 days [16]. However, appropriate coating of the nanoMOF surface is
desirable for several reasons: (i) An adequate coating may overcome nanoMOFs’ tendency to aggregate
in aqueous media thus providing colloidal stability to the system; (ii) it could control and modulate
drug release; and (iii) it could confer the nanoMOFs with biorecognition and targeting abilities to
reach their biological targets through recognition of specific receptors. In order to achieve these goals,
one strategy is to employ a noncovalent coating using saccharide derivatives that are large enough to
avoid penetration within the nanoMOF’s pores while conferring colloidal stability and modulated
drug release. Recently, we have reported a postsynthetic strategy using phosphorylated β-cyclodextrin
(β-CD) building-blocks for the preparation of a biocompatible nanoMOFs system [15,17]. Noncovalent
coatings were developed by attaching phosphate groups to the macrocycle that subsequently bind
the metallic sites on the nanoparticle surface. Advantageously, the procedure was carried out directly
in water in one step without using any toxic additives and led to coatings stable enough under
physiological conditions. β-CD was chosen because its dimensions are, as needed, large enough to
avoid penetration within the MIL-100(Fe) nanoMOFs pores [18], and their numerous free OH are
very suitable for introducing functional groups in the primary or/and secondary rims. In addition,
β-CD coatings were able to improve suspension stability and could be further functionalized with
fluorescent dyes.
Additionally, application of nanoparticles in biological media is strongly affected by their
interaction with proteins from the medium. When nanoparticles are exposed to a biological environment,
a fast adsorption of proteins onto their surfaces takes place, thus forming a NP-protein complex corona.
This so-called “protein corona” modifies the nanoparticles “identity” and triggers various biological
processes towards the nanoparticles including blood clearance and immunity response [19]. A potential
drug nanocarrier must avoid rapid clearance during the circulation time and should prevent fast
cellular uptake. In this regard, long chain polyethylene glycol (PEG) shells are used as a molecular
barrier that shields nanoparticles against protein adsorption and fast recognition by the immune
system, as it is proved that PEG has one of the lowest levels of protein absorption among all known
polymers [20]. Such PEG brushes confer “stealth” properties to the drug delivery systems and lead to a
decrease in cellular uptake. However, whereas PEG surface modification has been widely documented
in the case of liposomes and polymeric nanoparticles, only a few attempts have been made so far to
modify MIL-100(Fe) nanoMOFs with PEG [15,21].
A challenging issue concerning the development of MOF-based nanocarriers is their surface
functionalization with molecular recognition properties, so they can be used for specific targeting.
In this regard, biomolecules involved in biological recognition processes such as carbohydrates present
several advantages over other biomolecules [22,23]. In addition to contributing to the nanoparticle
biocompatibility and stability in aqueous media preventing aggregation, they are available on a large
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scale and relatively easy to chemically modify. Furthermore, they have been proven to provide
“stealth” properties comparable to those conferred by PEGylation, while barely affecting the molecular
recognition properties [24,25]. However, the interaction between carbohydrates and their specific
protein receptors, called lectins, are typically very weak when compared with other biological binding
events [26]. Nature uses a well-known strategy, named multivalent effect, to increase this low affinity by
gathering multiple copies of sugars to achieve a global binding potency toward their receptors higher
than that for the sum of the monovalent interactions [27]. Inspired by this natural approach, a vast
number of structures decorated with multiple carbohydrate moieties have been tested as potential
theranostic agents in biosensing and biomedicine [22,28,29].
Lectins are overexpressed in some tumor cells [30,31]. Thus, decorating nanoparticles of different
types with carbohydrates is an efficient approach to increase the local concentration of anticancer
drugs near tumor cells, facilitating specific cellular uptake through the specific binding between the
carbohydrate ligand and the overexpressed specific lectin [32,33]. Among this family of proteins,
mannose-binding lectins (MBLs) are overexpressed by many human cancer cells and may be used
as therapeutic targets [30]. Mannose has been used to target cells of the immune system such as
macrophages, dendritic cells, or Langerhans cells, as well as pathogenic microorganisms [34–36] and
cancer cells including retina, breast, and prostate, due to its high specificity to lectin receptors [37–39].
Moreover, it has been recently reported that PEGylated silicon nanoparticles (SiNPs) anchored with
mannose had a better “stealth” effect compared to PEGylated SiNPs in vivo [24]. Furthermore,
hydroxyethyl starch nanocarriers PEGylated and mannose-functionalized on the outer PEG layer not
only showed an efficient “stealth” effect, but also that the targeting moieties were accessible to the
biological receptors [25]. However, to the best of our knowledge, only a few examples of nanoMOFs
functionalized with mannose have previously been reported by some of us [15,17].
In this context, we describe a convenient preparation of tetraethylene glycol (TEG)-, PEG-, and
mannose-surface functionalized MIL-100(Fe) nanoMOFs. The preparation involved, first, the synthesis
of a series of phosphorylated β-CD scaffolds displaying motifs of mannose and/or TEG or PEG (average
MW ~2000) as coating building blocks, followed by a postsynthetic modification of MIL-100(Fe)
nanoMOFs by spontaneous self-assembly of the building blocks on their surfaces. We compare the
“stealthy” capacity of the surface-modified nanoMOFs to reduce the cellular uptake and to enhance the
retention time, avoiding capture by phagocytic cells. Mannosylated nanoparticles exhibit enhanced
binding affinity towards a model mannose-specific lectin concanavalin A (ConA) due to the globular
multivalent display of the mannose moieties on their surface, much like the glycocalyx [40]. Moreover,
we demonstrate that the coating method can be applied to drug-loaded MIL-100(Fe) nanoMOFs, using
anticancer drug doxorubicin (DOX).
2. Materials and Methods
2.1. Materials
Thin layer chromatography (TLC) was performed on Merck silica gel 60 F254 aluminum sheets
and developed by UV–vis light, iodine, 5% v/v sulfuric acid in ethanol, and/or 1% w/v potassium
permanganate in aqueous solution containing 0.1% w/v sodium hydroxide and 7% w/v potassium
carbonate, depending on the case. Flash column chromatography was performed on Merck silica gel
(230–400 mesh, ASTM). Melting points were measured on a Büchi B-450 melting point apparatus and
are uncorrected. Optical rotations were recorded on a Jasco P-1030 polarimeter at room temperature.
[α]D25 values are given in 10−1 deg cm−1 g−1. Infrared spectra were recorded on a Bruker Alpha
FTIR equipped with a Bruker universal ATR sampling accessory. 1H, 13C, and 2D NMR spectra were
recorded on a Bruker Avance III HD 600 MHz spectrometer equipped with a QCI 1H/13C/15N/31P
proton-optimized quadrupole inverse cryoprobe with 1H and 13C cryochannels, a Bruker Avance
III HD 500 MHz spectrometer equipped with an inverse TBI 1H/31P/BB probe, or a Bruker Nanobay
Avance III HD 300 MHz spectrometer equipped with a QNP 1H/13C/19F/31P probe, depending on the
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sample. Standard Bruker software was used for acquisition and processing routines. Chemical shifts
(δ) are given in parts per million (ppm) and referenced to internal tetramethylsilane (TMS) signal (δH,
δC 0.00). J values are given in hertz (Hz). MALDI-TOF mass spectra were recorded on a 4800 Plus AB
SCIEX spectrometer with 2,5-dihydroxybenzoic acid (DHB) as the matrix. ESI-TOF mass spectra were
measured on an Agilent LC/MSD-TOF spectrometer. Syringe filtering was conducted using nylon
0.45µm Milipore Millex® syringe-driven filter units. Dialysis was performed using Thermo ScientificTM
Slide-A-LyzerTM G2 2000 MWCO Dialysis Cassette. A Hanna HI 98192 EC/TDS/NaCl/Resistivity meter
was employed to monitor dialysate solutions conductivity during dialysis. Transmission electron
microscope (TEM) images were acquired on a JEOL 1400 microscope working at 120 kV. Dynamic light
scattering (DLS) measurements were performed on a Malvern Zetasizer Nano-ZS analyzer. Nitrogen
sorption experiments were conducted on a Micromeritics ASAP 2020 equipment. Inductively coupled
plasma mass spectrometry (ICP-MS) analysis was performed on an Agilent 8800 instrument equipped
with a triple quadrupole. Isothermal titration calorimetry (ITC) experiments were conducted on an
ultrasensitive Microcal VP-ITC calorimeter.
Acetic anhydride (Panreac, purum), per(6-azido-6-deoxy)-β-CD 1 (CycloLab L&D Ltd., Budapest,
Hungary), copper(I) bromide (Sigma-Aldrich, St. Louis, MI, USA, ≥99.9%), copper(I) iodide
(Aldrich, 98%), anhydrous copper(II) sulphate (Fluka, 98%), (+)-sodium l-ascorbate (NaAsc, Sigma,
BioXtra, ≥99%), phosphorus pentoxide (Panreac, purum), 1-methoxypentatetraconta(ethyle- ne
glycol) (Aldrich, Mn ~2000), 4-dimethylaminopyridine (DMAP, Fluka, ≥98%), methanesulfonyl
chloride (Fluka, ≥99%), tert-butyldimethylsilyl chloride (Sigma-Aldrich, Steinheim, Germany, 97%),
doxorubicin (DOX, Sigma-Aldrich, St. Louis, MI, USA, 98%), and β-CD phosphate sodium salt
(CD-P, Cyclolab L&D Ltd., Budapest, Hugary, DS 2–6), were purchased from commercial sources
and used without further purification unless otherwise indicated. β-CD (CycloLab L&D Ltd.,
Budapest, Hungary) was dried at 50 ◦C in vacuum in the presence of P2O5 until it reached a
constant weight before using. Propargyl 2,3,4,6-tetra-O-acetyl-α-d-mannopyranoside 2 was prepared
as described in literature [41,42] with small modifications. Specifically, purification of the compound
after deacetylation was carried out by flash column chromatography using EtOAc-MeOH 6:1 as
eluent. NMR data for this compound in D2O completely agreed with that described by van der Peet
et al. [43]. 1-Propargyloxy-3,6,9-trioxa-undecane-11-ol [44,45], 3,6,9,12-tetraoxapentadec-14-ynyl
2,3,4,6-tetra-O-acetyl-α-d-mannopyranoside 4 [46], heptakis(6-O-tert-butyldimethylsilyl-2,3-di-O-
propargyl)cyclomaltoheptaose 12 [47], and heptakis(2,3-di-O-propargyl)cyclomaltoheptaose 13 [47]
were prepared as described in literature. Pyridine (Panreac, purum), trimethylamine (Sigma-Aldrich,
≥99%), and organic solvents were dried according to literature procedures [48]. Dry DMF (AcroSeal,
99.8%, over molecular sieves) was purchased from Acros.
Iron (III) chloride hexahydrate (Alfa Aesar, 98%), 1,3,5-benzenetricarboxylic acid (BTC,
Sigma-Aldrich, St. Louis, MI, USA, 95%), and absolute ethanol (Carlo Erba, 99%,) were used for the
synthesis of nanoMOFs. CD-P was used for the coating of nanoMOFs along with the synthesized CD
phosphate salt derivatives 8–10 and 16. Dulbecco’s PBS solution was used for nanoMOFs Zeta potential
(ZP) measurements. Stability studies were performed in a complete cell culture medium (DMEM,
in Dulbecco’s Modified Eagle’s Medium (Thermo Fischer, Waltham, MA, USA) complemented with
10% FBS, 1% penicillin/streptomycin (100 mg/mL), and 1% l-glutamine). Deionized MilliQ water was
obtained from a Millipore apparatus with a 0.22 µm filter.
2.2. Synthesis of 1-O-propargyl-13-O-acetyl-1,4,7,10,13-pentaoxatridecane (3)
Acetic anhydride (3 mL, 0.032 mol) was added at 0 ◦C to a solution of 1-propargyloxy-3,6,9-tri-
oxa-undecane-11-ol (1.228 g, 5.287 mmol) in dry pyridine (6 mL, 0.074 mol) and left at room temperature
overnight. Solvent was rotary evaporated under high vacuum and the crude was purified by flash
column chromatography using 2:3→1:2 Hexane-EtOAc as eluent to give compound 3 (1.370 g,
4.994 mmol, 94%) as a colorless oil. Rf = 0.6 (1:2 Hexane-EtOAc); IR ν/cm−1 2872, 2116, 1733, 1238,
1095, 1049, 955, 919, 729; 1H-NMR (500 MHz, CDCl3), δ (ppm): 4.23–4.21 (m, 2H, H-12), 4.20 (d, 2H,
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J = 2.4 Hz, OCH2C≡), 3.71–3.68 (m, 6H, H-2,3,11), 3.67 (s, 4H, OCH2CH2O), 3.66 (s, 4H, OCH2CH2O),
2.43 (t, 1H, J = 2.4 Hz, ≡CH), 2.08 (s, 3H, CH3); 13C-RMN (125 MHz, CDCl3), δ (ppm): 171.1 (CO), 79.7
(C≡), 74.6 (≡CH), 70.7–70.5 (C-3,5,6,8,9), 69.2–69.1 (C-2,11), 63.7 (C-12), 58.5 (OCH2C≡), 21.0 (CH3);
ESI-TOF-MS m/z calcd. for C13H26NO6 292.1756, found 292.1755 (M + NH4)+; calcd. for C13H22NaO6
297.1309, found 297.1309 (M + Na)+.
2.3. Synthesis of Heptakis{6-deoxy-6-[4′-(2”,3”,4”,6”-tetra-O-acetyl-α-d-mannopyranosyloxymethyl)-1H-
1,2,3-triazol-1′-yl]}cyclomaltoheptaose (5)
A suspension of CuBr (426 mg, 2.97 mmol) in H2O (45 mL) was added to a preheated (100 ◦C)
solution of per(6-azido-6-deoxy)-β-CD 1 (200 mg, 0.142 mmol) and propargyl 2,3,4,6-tetra-O-acetyl-
α-d-mannopyranose 2 (47 mg, 0.213 mmol) in DMF (15 mL). The mixture was stirred for 1 h at 100 ◦C.
The solvent was evaporated under high vacuum and the residue was purified by a flash column
chromatography using 10:1→5:1 CH3CN-H2O. Subsequently, the product was passed through a short
pad of silica gel using 10:2:1 CH3CN-H2O-(30% v/v aq. NH3) as eluent. The collected fractions were
rapidly neutralized to pH ~7.0 by addition of 1 N HCl and extracted with CH2Cl2 (100 mL) to prevent
deacetylation. The organic layer was washed with H2O (2 × 100 mL), dried on Na2SO4, and evaporated
to yield compound 5 (2.6 g, 0.655 mmol, 86%) as a pale yellow solid: Rf = 0.2 [25:1:5 CH3CN-H2O-(30%
v/v aq. NH3)]; mp 96 ◦C; [α]D25 +70◦ (c 0.5, CH2Cl2); IR ν/cm−1 3418, 2934, 1748, 1372, 1230, 1048;
1H-NMR (500 MHz, DMSO-d6, 80 ◦C), δ (ppm): 7.96 (s, 7H, H-5′), 5.66–5.65 (m, 14H, OH), 5.13–5.10
(m, 21H, H-1,3”,4”), 5.06 (dd, 7H, 3J1”,2” = 1.6 Hz, 3J2”,3” = 3.0 Hz, H-2”), 4.91 (d, 7H, 3J1”,2” = 1.6, H-1”),
4.65 (d, 7H, 2J = 12.4 Hz, OCHa-C2HN3), 4.57 (dd, 7H, 2J6a,6b = 14.1 Hz, 3J5,6a = 2.5 Hz, H-6a), 4.48 (d,
7H, 2J = 12.4 Hz, OCHb-C2HN3), 4.46 (dd, 7H, 2J6a,6b = 14.1 Hz, 3J5,6b = 4.8 Hz, H-6b), 4.16 (dd, 2J6”a,6”b
= 12.2 Hz, 3J5”,6”a = 5.1 Hz, H-6”a), 4.13 (m, 7H, H-5), 4.07 (dd, 7H, 2J6”a,6”b = 12.2 Hz, 3J5”,6”b = 2.8 Hz,
H-6”b), 3.99 (ddd, 7H, 3J4”,5” = 9.7 Hz, 3J5”,6”a = 5.1 Hz, 3J5”,6”b = 2.8 Hz, H-5”), 3.76 (td, 7H, 3J = 9.5 Hz,
3J = 2.3 Hz, H-3), 3.33–3.29 (m, 7H, H-2), 3.26 (t, 7H, J = 9.2 Hz, H-4), 2.07 (s, 21H, CH3), 2.01 (s, 21H,
CH3), 1.99 (s, 21H, CH3), 1.89 (s, 21H, CH3); 13C-NMR (125 MHz, DMSO-d6, 80 ◦C), δ (ppm): 169.4,
168.9, 168.8, 168.7 (CO), 141.9 (C-4′), 125.7 (C-5′), 101.4 (C-1), 95.7 (C-1”), 82.2 (C-4), 72.0 (C-3), 71.6
(C-2), 69.1 (C-5), 68.5 (C-3”), 68.4 (C-2”), 67.8 (C-5”), 65.5 (C-4”), 61.6 (C-6”), 59.5 (OCH2-C2HN3), 49.1
(C-6), 19.9, 19.8, 19.7, 19.6 (CH3). MALDI-TOF-MS m/z calcd. for C161H217N21O98Na+ 4035.3, found
4035.9 (M+Na)+.
2.4. Synthesis of Heptakis(6-deoxy-6-{4′-[14”-O-acetyl-(2”,5”,8”,11”,14”-pentaoxatetradecyl)]-1H-1,2,3-tri-
azol-1′-yl})cyclomaltoheptose (6)
A suspension of CuI (300 mg, 1.58 mmol) in H2O (30 mL) was added to a preheated (100 ◦C)
solution of per(6-azido-6-deoxy)-β-CD 1 (413 mg, 0.32 mmol) and 1-O-propargyl-13-O-acetyl-
1,4,7,10,13-pentaoxatridecane 3 (1.73 g, 6.3 mmol) in DMF (30 mL). The mixture was stirred for
6 h at 100 ◦C. The reaction was followed by TLC using 5:1 1,4-dioxane-(30% v/v aq. NH3) as eluent
until only one spot at Rf = 0.4 was observed. The solvent was evaporated under high vacuum and the
residue was purified by a flash column chromatography using 10:1:2 CH3CN-H2O-(30% v/v aq. NH3)
as eluent. The collected fractions were rapidly neutralized to pH ~7.0 by addition of 1 N HCl and
extracted with CH2Cl2 (3 × 100 mL) to prevent deacetylation. The organic layer was washed with H2O
(1 × 50 mL), dried on MgSO4, filtered, and rotary evaporated to yield compound 6 (418 mg, 0.129 mmol,
41%) as a sticky pale yellow solid: Rf = 0.4 [5:1 1,4-dioxane-(30% v/v aq. NH3)]; [α]D25 +8◦ (c 0.25,
CH2Cl2); IR ν/cm−1 3354, 2873, 1734, 1237, 1091, 1045; 1H-NMR (500 MHz, DMSO-d6, 80 ◦C), δ (ppm):
7.86 (s, 7H, H-5′), 5.64 (bs, 14H, OH-2,3), 5.08 (d, 7H, 3J1,2 = 3.2 Hz, H-1), 4.45 (dd, 7H, 2J6a,6b = 14.5 Hz,
3J5,6a = 2.6 Hz, H-6a), 4.40 (d, 7H, 2J = 12.4 Hz, H-1”a), 4.34 (d, 7H, 2J = 12.4 Hz, H-1”b), 4.32 (dd, 7H,
2J6a,6b = 14.5 Hz, 3J5,6b = 7.9 Hz, H-6b), 4.11 (t, 14H, J = 5.0 Hz, H-13”), 4.10–4.07 (m, 7H, H-5), 3.75
(t, 7H, J = 9.2 Hz, H-3), 3.60 (t, 14H, J = 5.0 Hz, H-12”), 3.55–3.49 (m, 84H, H-2”,3”,6”,7”,9”,10”), 3.31
(dd, 7H, 3J2,3 = 9.6 Hz, 3J1,2 = 3.2 Hz, H-2), 3.28 (t, 7H, J = 9.4 Hz, H-4), 2.00 (s, 21H, CH3); 13C-NMR
(125 MHz, DMSO-d6, 80 ◦C), δ (ppm): 169.6 (CO), 143.4 (C-4′), 124.6 (C-5′), 101.3 (C-1), 82.4 (C-4), 72.0
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(C-3), 71.6 (C-2), 69.4–69.2 (C-2”,3”,6”,7”,9”,10”), 68.7 (C-5), 67.9 (C-12”), 63.1 (C-1”), 62.6 (C-13”), 49.1
(C-6), 20.0 (CH3); MALDI-TOF-MS m/z calcd. for C133H217N21O89Na+ 3252.4, found 3252.7 (M + Na)+.
2.5. Synthesis of Heptakis(6-deoxy-6-{4′-[14”-O-(2′′′,3′′′,4′′′,6′′′-tetra-O-acetyl-α-d-mannopyranosyl)-2”,
5”,8”,11”,14”-pentaoxatetradecyl]-1H-1,2,3-triazol-1′-yl})cyclomaltoheptose (7)
A suspension of CuSO4 (164 mg, 1.02 mmol) and sodium ascorbate (220 mg, 1.11 mmol) in
H2O (12 mL) was added to a preheated (65 ◦C) solution of per(6-azido-6-deoxy)-β-CD 1 (362 mg,
0.28 mmol) and compound 4 (1.4 g, 2.5 mmol) in DMF (25 mL). The mixture was stirred for 3 h at
100 ◦C. The reaction was followed by TLC using 5:1 1,4-dioxane-(30% v/v aq. NH3) as eluent. The
solvent was evaporated under high vacuum and the residue passed through a short pad of silica
gel using 20:6:1 CH3CN-H2O-(30% v/v aq. NH3) as eluent. The solution was freeze-dried and the
resulting material was further purified by a flash column chromatography using 2:2:1:0→20:20:10:1
CH2Cl2-CH3CN-EtOH-H2O as eluent to yield compound 7 (860 mg, 0.164 mmol, 60%) as a sticky
pale yellow solid after freeze-drying: Rf = 0.4 (5:1 1,4-dioxane-(30% v/v aq. NH3)); [α]D25 +27◦ (c 0.5,
CH2Cl2); IR ν/cm−1 2877, 1743, 1369, 1220, 1077, 1042, 732; 1H-NMR (500 MHz, DMSO-d6, 80 ◦C), δ
(ppm): 7.86 (s, 7H, H-5′), 5.65–5.64 (m, 14H, OH-2,3), 5.17 (dd, 7H, 3J3′′′,4′′′ = 10.1 Hz, 3J2′′′,3′′′ = 3.3
Hz, H-3′′′), 5.12 (dd, 7H, 3J2′′′,3′′′ = 3.3 Hz, 3J1′′′,2′′′ = 1.4 Hz, H-2′′′), 5.11 (t, 7H, J = 9.8 Hz, H-4′′′),
5.09 (d, 7H, 3J1,2 = 3.2 Hz, H-1), 4.90 (d, 7H, 3J1′′′,2′′′ = 1.4 Hz, H-1′′′), 4.47 (dd, 7H, 2J6a,6b = 14.7 Hz,
3J5,6a = 2.7 Hz, H-6a), 4.40 (d, 7H, 2J1”a,1”b = 12.4 Hz, H-1”a), 4.35 (bd, 7H, J = 14.1 Hz, H-6b), 4.34 (d,
7H, 2J1”a,1”b = 12.4 Hz, H-1”b), 4.15 (dd, 7H, 2J6′′′a,6′′′b = 12.2 Hz, 3J5′′′,6′′′a’ = 5.2 Hz, H-6′′′a), 4.11–4.09
(m, 7H, H-5), 4.08 (dd, 7H, 2J6′′′a,6′′′b = 12.2 Hz, 3J5′′′,6′′′b = 2.9 Hz, H-6′′′b), 4.01 (ddd, 7H, 3J4′′′,5′′′ = 9.6
Hz, 3J5′′′,6′′′a = 5.2 Hz, 3J5′′′,6′′′b = 2.0 Hz, H-5′′′), 3.77–3.75 (m, 7H, H-3), 3.74 (t, 7H, J = 4.5 Hz, H-13”a),
3.66 (dd, 7H, 2J = 9.6 Hz, 3J = 5.1 Hz, H-13”b), 3.62 (dd, 14H, J = 9.6 Hz, J = 5.0 Hz, H-12”), 3.57–3.48 (m,
84H, H-3”,4”,6”,7”,9”11”), 3.34–3.29 (m, 7H, H-2), 3.27 (t, 7H, J = 9.4 Hz, H-4), 2.10 (s, 21H, CH3), 2.01
(s, 21H, CH3), 2.00 (s, 21H, CH3), 1.93 (s, 21H, CH3); 13C-NMR (125 MHz, DMSO-d6, 80 ◦C), δ (ppm):
169.3 (CO), 168.9 (CO), 168.8 (CO), 167.8 (CO), 143.4 (C-4′), 124.7 (C-5′), 101.3 (C-1), 96.5 (C-1′′′), 82.4
(C-4), 72.0 (C-3), 71.6 (C-2), 69.5–69.4 (OCH2CH2O), 69.3 (C-5), 68.9 (C-12”), 68.7 (OCH2CH2O), 68.6
(C-2′′′), 68.4 (C-3′′′), 67.7 (C-5′′′), 66.4 (C-13”), 65.6 (C-4′′′), 63.1 (C-1”), 61.8 (C-6′′′), 49.1 (C-6), 19.9
(CH3), 19.8 (CH3), 19.7 (CH3), 19.6 (CH3); MALDI-TOF-MS m/z calcd. for C217H329N21O126 5245.00,
found 5245.7 (M)+; calcd. for C217H329N21O126Na+ 5268.0, found 5267.6 (M + Na)+.
2.6. Synthesis of Heptakis{6-deoxy-6-[4′-(α-d-mannopyranosyloxymethyl)-1H-1,2,3-triazol-1′-yl]}cyclomal-
toheptaose Phosphate Sodium Salt (8)
P2O5 (2.7 g, 19 mmol) was suspended in dry DMF (40 mL) and sonicated for 30 min, then
compound 5 (1.25 g, 0.311 mmol) was added and the mixture was stirred at 40 ◦C until no starting
material was detectable (after 4 h) by TLC [2:1:2 CH3CN-H2O-(30% v/v aq. NH3)]. The mixture was
then stirred for 12 h at room temperature at pH 11–13, which was maintained by addition of 1 M
aqueous NaOH as needed. The solution was then neutralized with 5% aqueous HCl and the solvent
was rotary evaporated under high vacuum. The residue was dissolved in the minimum amount of
H2O, syringe filtered (nylon 0.45 µm), and dialyzed (2000 MWCO) against distilled water by changing
dialysate solution every 3 h until its conductivity was stable and below 1 µS/cm (5 days for final
value of 0.96 µS/cm) to yield 8 (1.3 g) as a white solid after lyophilization: mp 250 ◦C (dec); IR ν/cm−1
3420, 2933, 2790, 1645, 1255, 1126, 1052, 977, 889, 537; 1H-NMR (600 MHz, D2O), δ (ppm): 8.12 (bs,
H-5′), 5.32–5.21, 4.8–4.11 (overlapped with HDO), 3.83–3.52; 13C-NMR (150 MHz, D2O), δ (ppm): 143.4
(C-4′), 126.9 (C-5′), 99.3 (C-1”), 72.9, 72.0, 70.4, 69.8, 66.6, 60.8 (C-6”), 59.5 (OCH2-C2HN3), 50.5 (C-6);
13P-RMN (242.9 MHz, D2O), δ (ppm): 0.71 (orthophosphates), −8.38 (pyrophosphates), −21.51–(−23.65)
(polyphosphates); HR-ICP-MS: P 16.3%.
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2.7. Synthesis of Heptakis{6-deoxy-6-[4′-(13”-hydroxy-2”,5”,8”,11”-tetraoxatridecyl)-1H-1,2,3-triazol-1′-
yl]}cyclomaltoheptose Phosphate Sodium Salt (9)
P2O5 (2.067 g, 14.560 mmol) was suspended in dry DMF (13 mL) and sonicated for 30 min, then
compound 6 (847 mg, 0.260 mmol) was added and the mixture was stirred at 40 ◦C until no starting
material was observed (after 4 h) by TLC [5:1 1,4-dioxane-(30% v/v aq. NH3)]. The mixture was
then stirred for 12 h at room temperature at pH 11–13, which was maintained by addition of 1 M
aqueous NaOH as needed. The solution was then neutralized with 5% aqueous HCl and the solvent
rotary evaporated under high vacuum. The residue was dissolved in the minimum amount of H2O,
syringe filtered (nylon 0.45 µm), and dialyzed (2000 MWCO) against distilled water by changing
dialysate solution every 3 h until its conductivity was stable and below 1 µS/cm (5 days for final value
of 0.90 µS/cm) to yield 9 (669 mg) as a white solid after lyophilization: mp 160 ◦C; IR ν/cm−1 3432,
2922, 2877, 1640, 1267, 1090, 946, 522; 1H-NMR (600 MHz, D2O), δ (ppm): 7.94 (bs, H-5′), 5.11 (bs,
H-1), 4.66–3.96 (m, H-1”,3,5,6a,b), 3.55–3.46 (m, H-2,3”,4,4”,6”,7”.9”,10”,11”,12”); 13C-NMR (150 MHz,
D2O), δ (ppm): 143.8 (C-4′), 126.8 (C-5′), 99.7 (C-1), 81.7, 79.1, 75.7–73.9, 71.7 (OCH2CH2O), 70.2,
69.5–69.0 (OCH2CH2O), 63.0 (C-1”), 60.3 (C-13”), 50.4 (C-6); 13P-RMN (242.9 MHz, D2O), δ (ppm): 0.20
(orthophosphates), −9.69 (pyrophosphates), −21.57–(−23.65) (polyphosphates); HR-ICP-MS: P 15.7%.
2.8. Synthesis of Heptakis{6-desoxi-6-{4′-[14”-O-(α-d-mannopyranosyl)-2”,5”,8”,11”,14”-pentaoxatetrade-
cyl]-1H-1,2,3-triazol-1′-yl}}ciclomaltoheptose Phosphate Sodium Salt (10)
P2O5 (510 mg, 3.6 mmol) was suspended in dry DMF (13 mL) and sonicated for 30 min, then
compound 7 (356 mg, 0.068 mmol) was added and the mixture was stirred at 40 ◦C until no starting
material was observed (after 5 h) by TLC [5:1 1,4-dioxane-(30% v/v aq. NH3)]. The mixture was then
stirred for 12 h at room temperature at pH 11–13, which was maintained by addition of 1 M aqueous
NaOH as needed. The solution was then neutralized with 5% aqueous HCl and the solvent rotary
evaporated under high vacuum. The residue was dissolved in the minimum amount of H2O, syringe
filtered (nylon 0.45 µm), and dialyzed (2000 MWCO) against distilled water by changing dialysate
solution every 3 h until its conductivity was stable and below 1 µS/cm (5 days for final value of
0.98 µS/cm) to yield 10 (806 mg) as a white solid after lyophilization: mp 110 ◦C; IR ν/cm−1 3431, 2923,
1643, 1271, 1092, 1030, 975, 529; 1H-NMR (600 MHz, D2O), δ (ppm): 8.07 (bs, H-5′), 5.23–5.16, 4.55–4.10
(overlapped with HDO), 3.97, 3.88–3.82, 3.78–3.75, 3.72–3.65; 13C-NMR (150 MHz, D2O), δ (ppm): 143.8
(C-4′), 126.8 (C-5′), 100.0 (C-1,1′′′) 79.1, 75.2, 72.7, 71.7, 70.5, 70.0, 69.6, 69.5, 69.0, 67.4 66.7, 66.4 (C-13”),
63.0 (C-1”), 60.9 (C-6′′′), 50.3 (C-6); 13P-RMN (242.9 MHz, D2O), δ (ppm): 0.90 (orthophosphates),
−7.09–(−8.06) (pyrophosphates), −21.01–(−23.66) (polyphosphates); HR-ICP-MS: P 19.9%.
2.9. Synthesis of Heptakis(6-O-tert-butyldimethylsilyl)cyclomaltoheptaose (11)
Compound 11 was prepared as described in literature [49] with a new purification protocol.
Specifically, tert-butyldimethylsilyl chloride (5.577 g, 37.002 mmol) was added to a solution of β-CD
(5 g, 4.405 mmol) in dry pyridine (80 mL) under nitrogen atmosphere and stirred at room temperature
for 12 h. The reaction was followed by TLC (30:5:4 EtOAc–96% v/v EtOH–H2O), which showed three
spots at Rf = 0.7, 0.6, and 0.3 identified as oversilylated byproducts, derivative 11, and undersilylated
species, respectively. Portions of TBDMSCl (664 mg, 4.405 mmol) were added every 12 h until the
most polar product was consumed. Water (500 mL) was added and the resulting solid was filtered,
washed with water (250 mL), and azeotropically dried with toluene (3 × 150 mL). The residue was
purified by a short (5 cm) flash chromatography using 40:40:20:4 CH2Cl2–MeCN–96% v/v EtOH–30%
v/v aqueous NH3 as eluent until the TLC spot at Rf = 0.73 completely eluted. The eluent was then
changed to 40:40:20:4 CH2Cl2–MeCN–96% v/v EtOH–H2O to yield 2 as a white powder which was
dried at 50 ◦C under high vacuum until constant weight (7.302 g, 3.778 mmol, 86%). NMR data agreed
with those previously reported [49]: 1H NMR (500 MHz, CDCl3), δ (ppm): 6.74 (bs, OH), 5.27 (bs, OH),
4.89 (d, 7H, J1,2 = 3.5 Hz, H-1), 4.04 (t, 7H, J = 9.2 Hz, H-3), 3.90 (dd, J6,6′ = 11.3 Hz, J5,6 = 2.9 Hz, H-6),
3.71 (bd, 7H, J = 10.5 Hz, H-6′), 3.64 (dd, 7H, J2,3 = 9.6 Hz, J1,2 = 3.5 Hz, H-2), 3.62 (bs, 7H, H-5), 3.56
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(t, 7H, J = 9.2 Hz, H-4), 0.87 (s, 63H, SiC(CH3)3), 0.04 (s, 21H, SiCH3), 0.03 (s, 21H, SiCH3); 13C NMR
(125 MHz, CDCl3), δ (ppm): 102.1 (C-1), 81.9 (C-4), 73.7 (C-2), 73.5 (C-3), 72.7 (C-5), 61.8 (C-6), 26.0
(SiC(CH3)3), 18.4 (SiC(CH3)3), −4.9 (SiCH3), −5.0 (SiCH3).
2.10. Synthesis of 1-azido-1-deoxy-ω-O-methoxypentatetraconta(ethylene glycol) (14)
A solution of 1-methoxypentatetraconta(ethylene glycol) (35 g, 17.375 mmol), DMAP (428 mg,
3.5 mmol), and distilled Et3N (5.6 mL, 40.250 mmol) in CH2Cl2 (40 mL) was cooled to 0 ◦C under inert
atmosphere. MsCl (2.7 mL, 35 mmol) was added dropwise over 15 min and the mixture was stirred at
0 ◦C for 30 min and overnight at room temperature. The reaction mixture was then diluted with CH2Cl2
(50 mL) and washed with a 5% v/v aqueous HCl solution (3 × 50 mL) and brine (50 mL). The organic
phase was dried over MgSO4, filtered, and concentrated under reduced pressure to dryness. The
solid was subsequently dissolved in dry DMF (40 mL) and NaN3 (2.276 g, 35 mmol) was added. The
mixture was stirred at 60 ◦C for 24 h before the solvent was rotary evaporated under high vacuum. The
residue was suspended in THF (20 mL), sonicated (5 min), and the solid filtered off. The clear organic
filtrate was rotary evaporated, and the resulting solid was suspended in Et2O (50 mL), sonicated (5
min), and filtered. The solid was dissolved in H2O (100 mL) and extracted with CH2Cl2 (3 × 100 mL).
The organic phases were combined, dried (MgSO4), rotary evaporated, and the residue dried under
vacuum to give compound 14 (26.225 g, 12.858 mmol, 74%) as a slightly yellow powder: FT-IR (KBr)
ν/cm−1: 2868, 2105, 1093, 948, 842, 729; 1H NMR (300 MHz, D2O), δ (ppm): 3.96–3.93 (m, 13C satellite
peaks), 3.75–3.68 (m, 176H, OCH2CH2O), 3.65–3.61 (m, 2H, CH2CH2N3), 3.53–3.49 (m, 2H, CH2N3),
3.49–3.46 (m, 13C satellite peaks), 3.38 (s, CH3O); 13C NMR (75 MHz, D2O), δ (ppm): 71.7 (CH3OCH2),
70.3 (OCH2CH2O), 70.2 (CH3OCH2CH2O), 70.0 (OCH2CH2N3), 58.8 (CH3O), 50.9 (CH2N3).
2.11. Synthesis of Heptakis{2,3-di-O-{1′-[methoxypentatetraconta(ethylene glycol)yl-1H-1,2,3-triazol-4′-yl]-
methyl}}cyclomaltoheptaose (15)
A solution of heptakis(2,3-O-propargyl)cyclomaltoheptaose 13 (70 mg, 0.042 mmol), 1-azido-1-
deoxy-ω-O-methoxypentatetraconta(ethylene glycol) 14 (1.439 g, 0.706 mmol), and CuBr (16 mg,
0.118 mmol) in dry DMF (10 mL) under N2 atmosphere was stirred at 100 ◦C for 24 h. After that period
of time, starting compound 13 was not detectable by TLC (Rf = 0.47 in 30:5:4 EtOAc-EtOH-H2O). The
reaction mixture was cooled down and the solvent was rotary evaporated. The crude was purified by
column chromatography (5:1 MeCN-30% v/v aqueous NH3) to yield compound 15 (716 mg, 0.024 mmol,
57%) as a yellowish powder: mp 51 ◦C; IR (KBr) ν 3443, 2911, 2878, 1642, 1352, 1102, 952, 580 cm−1;
1H-RMN (600 MHz, D2O), δ (ppm): 8.00 (s, 7H, H-5′), 7.98 (s, 7H, H-5′), 5.25 (bs, 7H, H-1), 4.98 (bs,
7H, OCHa-C2HN3), 4.79–4.75 (m, OCHb-C2HN3, overlapped with HDO), 4.55 (bs, 14H, CH2N), 4.50
(bs, 14H, CH2N), 4.05–3.53 (m, H-2,3,4,5,6a,b, OCH2CH2O), 3.86–3.84 (m, 13C satellite peaks), 3.62–3.60
(m, 13C satellite peaks), 3.41 (s, 42H, CH3O); 13C-RMN (150 MHz, D2O), δ (ppm): 144.9 (C-4′), 144.3
(C-4′), 125.2 (C-5′), 124.7 (C-5′), 97.6 (C-1), 80.6 (C-3), 78.1–77.8 (C-2,4), 71.0 (CH2OCH3), 69.6–68.7 (C-5,
OCH2CH2O), 65.9 (OCH2-C2HN3), 63.3 (OCH2-C2HN3), 60.4 (C-6), 58.1 (CH3O), 49.9 (CH2N).
2.12. Synthesis of Heptakis{2,3-di-O-{1′-[methoxypentatetraconta(ethylene glycol)yl-1H-1,2,3-triazol-4′-yl]-
methyl}}cyclomaltoheptaose Phosphate Sodium Salt (16)
P2O5 (30 mg, 0.208 mmol) was added to dry DMF (2 mL) and the mixture was sonicated in a
tightly closed flask for 30 min. Compound 15 (300 mg, 0.010 mmol) was then added to the solution
and the resulting mixture was stirred at 40 ◦C for 3 h. The mixture was cooled down and pH was
adjusted to ~7.0 using 1N NaOH. The solvent was rotary evaporated and the residue was dissolved in
the minimum amount of H2O, syringe filtered (nylon 0.45 µm), and dialyzed (2000 MWCO) against
distilled water by changing dialysate solution every 3 h until its conductivity was stable and below
1 µS/cm (5 days for final value of 0.90 µS/cm) to yield 16 (381 mg) as a white solid after lyophilization:
mp 49 ◦C (dec); IR (KBr) ν 3444, 2914, 2879, 1640, 1294, 1255, 1104, 524 cm−1; 1H-RMN (600 MHz,
D2O), δ (ppm): 7.92 (bs, 14H, H-5′), 4.79 (bs, H-1, OCH2-C2HN3, overlapped with HDO), 4.54 (bs, 14H,
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CH2N), 3.91–3.53 (m, H-2,3,4,5,6a,b, OCH2CH2O), 3.86–3.84 (m, 13C satellite peaks), 3.62–3.60 (m, 13C
satellite peaks), 3.41 (s, 42H, CH3O); 13P-RMN (242.9 MHz, D2O), δ (ppm): 0.44 (orthophosphates),
–9.33 (pyrophosphates), −21.47–(−23.88) (polyphosphates); HR-ICP-MS: P 8.0%.
2.13. Synthesis and Characterization of MIL-100(Fe) nanoMOFs
Iron trimesate nanoMOFs were synthesized using a microwave-assisted hydrothermal method
described elsewhere [10,15]. Briefly, 30 mL of an aqueous mixture containing 6.0 mM iron chloride
hexahydrate and 4.0 mM of BTC was heated at 130 ◦C under stirring for 6 min by microwave
irradiation at 1600 W (Mars-5, CEM Corporation, Matthews, NC, USA). The synthesized nanoMOFs
were recovered by centrifugation at 10,000 g for 15 min and purified by six times washing with
absolute ethanol. Their morphology was observed with a transmission electron microscope. Mean
hydrodynamic diameters and size distributions were determined by DLS. NanoMOFs’ zeta potential
(ZP) was measured at 25 ◦C by DLS in 10 mM PBS pH 7.4. For this, nanoMOFs were diluted to a final
concentration of 100 µg/mL using Dulbecco’s PBS solution. The nanoMOF Brunauer–Emmett–Teller
(BET) surface area was measured by nitrogen sorption experiments at −196 ◦C after sample degassing
at 100 ◦C for 15 h under high vacuum. X-ray powder diffraction (XRPD) patterns were recorded for
crystallinity characterization. NanoMOFs were stored in ethanol at room temperature, and centrifuged
and re-suspended in aqueous media whenever needed.
2.14. Surface Modification of MIL-100(Fe) nanoMOFs and Their Characterization
NanoMOFs were centrifuged at 10,000 g for 10 min to remove the storage solvent (ethanol) and
then redispersed in water by vortex at final concentration of 2 mg/mL. For coating, equal volumes
of nanoMOFs suspensions and phosphorylated CD derivatives (PCDs) CD-P, 8–10 or 16 solutions at
0.02, 0.2, 0.4, and 0.6 mg/mL (corresponding to nanoMOFs:PCDs 100:1, 10:1, 5:1, and 3:1 mass ratios,
respectively) were incubated overnight at room temperature.
Nonattached coating PCDs molecules were removed by centrifugation (10000 g, 10 min). The
pellets were dried and the amount of attached PCDs (CD-P, 8–10 or 16) was quantified by ICP-MS.
Briefly, uncoated and coated nanoMOFs were digested using aqua regia (15 min under ultrasonic
bath), and phosphorous (P) quantification was performed by ICP-MS. Operation conditions were daily
optimized using a tuning solution. P isotope was detected using “mass shift mode” (47PO+) after
reaction with oxygen in the cell. Conversely, scandium (Sc) (added as internal standard on samples
and calibration standards solutions at a concentration of 10 µg L−1) was detected on “mass mode”
(45Sc+). Oxygen was introduced into the collision/reaction cell at a flow rate of 0.35 mL min−1. Dwell
time for each of the targeted isotopes was 1 s. P was quantified using external calibration prepared
using certified 1000 mg L−1 P standard solution (Merck, Darmstadt, Germany).
The amount of PCDs associated to nanoMOF was calculated on the basis of their P content by
Equation (1):
PCDs adsorption (%) =
(P wt%)sample
(P wt%)PCDs
× 100 (1)
where (P wt%)PCDs is the phosphorous content in the PCDs coating agents (CD-P, 8–10 or 16).
Uncoated and coated nanoMOFs were characterized to determine their size distribution,
morphology, and surface charge. The crystallinity of PCDs-coated nanoMOF was characterized
by X-ray powder diffraction (XRPD). The XRPD data were acquired using an in-house setup based
on a copper rotating anode generator (RU-200BEH, Rigaku Ltd., Tokyo, Japan). The X-ray beam
was filtered and focused by a confocal system consisting of two perpendicular graded multilayer
mirrors (CMF-12-38Cu6 from Osmic Inc., Cleveland, OH, USA). The samples were contained in round
glass capillaries (WJM-Glas Müller GmbH, Berlin, Germany), 1.5 mm in diameter, and mounted on a
homemade motorized sample holder. The scattering signal was detected by a CCD detector cooled
down to −30 ◦C (Photonic Science, Saint Leonards-on-sea, UK). The sample-to-detector distance was
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296 mm, yielding an accessible scattering vector range of 0.035–0.5 Å−1. The images were integrated,
corrected, and calibrated using the Nika suite (version 1.74) running in Igor Pro 7.08.
The PCDs-coated nanoMOF colloidal stabilities were estimated in complete cell culture medium
by measuring hydrodynamic diameters using DLS after 6 h incubation at 37 ◦C in cell culture media.
2.15. Quantification of nanoMOFs Uptake by Macrophage Cells
Macrophage cells (J774A.1) were seeded in 24-well plates at a density of 3.0 × 105 cells per well in
cell culture medium and kept overnight at 37 ◦C in 5% CO2. Cells were then incubated with 1 mL
cell culture media containing uncoated or coated nanoMOFs (50 µg mL−1) for 4 h. After incubation,
the cells were washed with PBS three times to eliminate the nanoMOFs which did not interact with
the cells. Cells were finally dried and digested using aqua regia (15 min under ultrasonic bath). Fe
quantification was performed by ICP-MS. Operation conditions were daily optimized using a tuning
solution. Fe and Co isotopes (added as internal standard on samples and calibration standards solution
at a concentration of 10 µg L−1) were detected using “on-mass mode” (54Fe+, 56Fe+, 59Co+). Helium
was introduced into the collision/reaction cell at a flow rate of 3 mL min−1. Dwell time for each of
the targeted isotopes was 1 s. Fe was quantified using external calibration prepared using certified
1000 mg L−1 Fe standard solution (Merck, Darmstadt, Germany).
2.16. Surface Modification of Doxorubicin (DOX)-Loaded MIL-100(Fe) Nanomofs with 9
An ethanolic suspension of MIL-100 (Fe) nanoMOFs was centrifuged (10 min, 10,000 g) and the
sediment redispersed in MilliQ water. The nanoMOF aqueous suspension was further mixed with a
DOX aqueous solution in 1:5 DOX:nanoMOFs weight ratio. The mixture was maintained under gentle
stirring for 48 h at room temperature. The DOX-loaded nanoMOFs were recovered by centrifugation (10
min, 10,000 g) and the supernatants were used to quantify the drug payload according to Equation (2):
Payload (%) =
Encapsulated Drug(mg)
nanoMOFs (mg)
× 100 (2)
The DOX-loaded nanoMOFs were further surface modified by incubation with an aqueous
solution of 9 overnight. After surface functionalization, DOX-loaded nanoMOFs@9 were recovered by
centrifugation (10 min, 10000 g). The supernatant was also recovered to quantify the DOX amount.
2.17. Isothermal Titration Calorimetry (ITC) Measurements
Canavalia ensiformis (Jack bean) concanavalin A (ConA) lectin (Sigma, type VI, lyophilized powder)
was used as received. All solutions were prepared in buffered MilliQ water (18.2 MΩcm), degassed for
10 min, and thermostated at 25 ◦C prior to each experiment. In the case of conjugates 8 and 10, 20 mM
phosphate buffer (pH 7.2) was used for both lectin and conjugates, which were considered as analyte
and titrating agents, respectively. On the other hand, 10 mM TRIS buffer (pH 7.5) was employed for
both lectin and nanoMOFs@8 and nanoMOFs@10, which were defined as titrating agent and analytes,
respectively. In all cases, lectin solution concentrations were determined by UV-Vis spectroscopy
(A1%280 nm = 13.7 for the tetrameric form). ITC experiments were conducted as previously described
elsewhere [50]. After calibrating the calorimeter as recommended by the manufacturer, the reference
and sample cells were filled with the corresponding pure buffer and the analyte solution, respectively,
while a 250 µM syringe was filled with the solution of the respective titrating agent (Supplementary
Materials, Table S2). The sample cell solution was continuously stirred at 416 rpm while the titrating
agent solution was injected in 8 µL aliquots every 5 min. The titrating agents were also injected into the
corresponding buffer in separate experiments in order to obtain the dilution background profiles, which
turned out to be similar to the heat signals detected after saturation in the interaction experiments with
the analytes. Obtained thermograms depicted the transfer of heat per second following each injection
of the titrating agent into the analyte solution as a function of time. The integration of each peak gave
Nanomaterials 2019, 9, 1103 11 of 26
the amount of heat generated by each injection after subtracting the titrating agent dilution heat. The
best fit of the experimental data to the model of n equal and independent sites provided the binding
constant and the thermodynamic profile along with the corresponding standard deviations. For these
calculations, we assumed that ∆H = ∆H0, while the changes in the standard free energy (∆G0) and
entropy (∆S0) were calculated as ∆G0 = −RTlnK and T∆S0 = ∆H − ∆G0, respectively.
3. Results and Discussion
3.1. Synthesis of Phosphate β-CD Derivatives (PCDs)
We carried out the synthesis of per-functionalized β-CD phosphate derivatives from
per-6-azido-6-deoxy-β-CD 1 (Scheme 1) for their use as coating agents in the postsynthetic surface
modification of the iron-based nanoMOFs MIL-100(Fe). Per-6-azido compound 1 was a convenient
starting material for the attachment on its primary face of seven appendages by Cu(I)-catalyzed
alkyne-azide cycloaddition reaction (CuAAC) [51–53]. As its azide counterpart, a terminal alkyne
group was required on the motifs intended to be attached to the macrocycle. Thus, we performed the
reaction of 1 with acetylated propargyl derivatives 2–4 containing mannose and/or TEG residues.
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e fi t t t t synthesis of compound 5 with seven acetylated mannopyranos residues
by coupling propargyl 2,3,4,6-tetra-O-acetyl-α-d-mannopyranoside (2) to perazide 1 in the pr sence
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of CuI(C2H5O)3P as catalyst in DMF at 100 ◦C. These conditions afforded a mixture, whose TLC
showed different spots with very close Rf which turned out to be very difficult to separate by column
chromatography using 25:1:5 CH3CN-H2O-(30% v/v aq. NH3) as eluent. We observed that small
variations in the eluent proportions sharply changed the column performance. However, a small
amount of the pure product was obtained, and HPLC-MS and MALDI-TOF mass spectra allowed the
detection of the target compound together with a number of under-substituted analogues, including one
derivative bearing an amino group as a result of a partial reduction. In order to optimize the conversion
to 5, other copper catalysts (CuI, CuBr), solvents, and reaction temperatures were tested. By performing
the reaction with CuBr in a 3:7 H2O-DMF mixture, the desired compound was obtained as a white solid
in 86% yield after a purification that included removal of copper traces. The molecular weight of 5 was
confirmed by MALDI-TOF mass spectrometry, which showed the m/z pick corresponding to [M+Na]+
ion. The formation of the triazole rings was confirmed by 1H NMR spectroscopy as it showed a peak
at δ 7.96 ppm corresponding to the triazole proton along with the absence of the triplet at δ 2.47 ppm
of the alkyne proton of the starting mannoside. In addition, 13C NMR spectrum also showed peaks at
δ 141.9 and 125.7 ppm corresponding to the C-4’ and C-5’ of the triazole rings, respectively. Both 1H
and 13C NMR spectra also revealed DMF residual peaks (Supplementary Materials, Figures S2 and
S12). The efforts made to remove the solvent from the sample, including lyophilization, azeotropic
distillation with toluene, and high vacuum at 50 ◦C, turned out to be unsuccessful. It is noteworthy
that NMR spectra for 5 were recorded in DMSO-d6 at 80 ◦C to overcome the conformational energy
barriers of the molecule. NMR spectra at 25 ◦C showed several sets of signals indicating that the
interconversion among different conformers of the structure were slow enough in the time scale of the
experiments, probably due to the steric hindrance on the primary face of the macrocycle. In sharp
contrast, increasing the temperature to 80 ◦C led to well-defined signals for each nuclei, confirming the
C7 symmetry of the molecule, and hence the presence of seven appendages on the macrocycle.
The synthesis of compound 6 bearing seven acetylated tetraethylene glycol branches also turned
out to be troublesome. A set of catalysts and conditions were tested, and the obtained crude products
were analyzed by TLC and HPLC-MS. Among the screened sets-up, CuI in 1:1 DMF-H2O at 100 ◦C
was found to be optimal for the cycloaddition reaction, affording 6 in 41% yield after purification. The
low yield can be attributed to a partial deacetylation during the column elution, judging from TLC (5:1
1,4-dioxane-30% v/v aq. NH3). MALDI-TOF confirmed the molecular weight of the target compound,
which showed the m/z peak corresponding to [M + Na]+ ion. The formation of the triazole rings (peak
at δ 7.86 ppm in the 1H-NMR spectrum) and the presence of acetyl moieties (peaks at δ 2.00 ppm
in 1H NMR spectrum, and at δ 169.6 (carboxyl) and 20.0 ppm (methyl) in 13C NMR spectrum) were
unambiguously confirmed by NMR spectroscopy. As in the case of derivative 5, recording the NMR
spectra in DMSO-d6 at 80 ◦C was mandatory in order to obtain single, well-defined signals for nuclei
of the glucose units of the macrocycle, thus confirming the C7 symmetry of the molecule due to the
per-modification at C-6 positions.
Next, CD derivative 7 (Scheme 1) decorated with seven acetylated mannose residues linked
through a tetraethylene glycol (TEG) tether was prepared. In this case, among the tested reaction
conditions the use of CuSO4 and sodium ascorbate as catalyst promoters in 2:1 DMF-H2O at 100 ◦C
resulted to be optimal and gave 7 in 60% yield after purification. The structure of 7 was confirmed
by MALDI-TOF mass spectrometry and NMR spectroscopy. 1H NMR spectrum of 7 measured in
DMSO-d6 at 80 ◦C showed a singlet corresponding to the triazole hydrogen at δ 7.86 ppm, two doublets
at δ 5.09 and 4.90 ppm corresponding to the anomeric protons of the glucose units of the macrocycle
(H-1) and the mannose residues (H-1′′′), respectively, and four singlets at δ 2.10–1.93 ppm assignable
to the 28 acetyl groups of the mannose units. The presence of the TEG tether was confirmed by the
multiplet that appeared in the range of δ 3.57–3.48 ppm corresponding to the CH2 groups of chain.
β-CD derivatives 5–7 presented fourteen free OH groups on the secondary face of the macrocycle
still available for further modifications. In order to transform these compounds into potential coating
agents for iron-based nanoMOFs MIL-100(Fe) [15,17], we decided to phosphorylate those OH to
Nanomaterials 2019, 9, 1103 13 of 26
yield phosphates 8–10 (Scheme 1). Phosphorylations of 5–7 were carried out by treatment with an
excess of P2O5 in DMF at 40 ◦C. After the starting material was consumed, pH was increased to ~13
to remove the acetyl groups of the primary face appendages. The crude products were dialyzed
towards distilled water. Based on the theoretical molecular weight of phosphates 8–10 by considering
fourteen disodium phosphate groups on the secondary face (4572.71–5804.73 Da), membranes of
500–1000 Da MWCO were initially chosen. However, intense peaks of unknown impurities at around
δ 8.40, 3.30, and 2.70 ppm were observed in the 1H NMR spectra of the dialyzed products. Increasing
membrane pore size to 2000 MWCO effectively removed the peaks at around δ 8.40 and 3.30 ppm,
although it did not affect to the signal at ca. δ 2.70 ppm and significantly decreased the obtained
amount of compounds 8–10. Both 1H and 13C NMR spectra of 8–10 confirmed the absence of the
peaks corresponding to acetyl groups presents in the starting materials 5–7 and showed broad signals
for the nuclei of both the macrocycle and the appendages. It is important to highlight that random
phosphorylation with P2O5 yields a mixture of ortho-, pyro-, and polyphosphates depending on the
molar ratio between the hydroxyl groups and the added amount of P2O5, but also on the presence of
traces of water during the reaction. Indeed, 31P NMR spectra showed, in all cases, three sets of signals
at around δ 0.5, −8.0, and −22.5 ppm corresponding to the ortho-, pyro-, and polyphosphate species,
respectively [54], formed on the secondary face of the macrocycles. Furthermore, we determined
the contents of P in derivatives 8–10 by HR-ICP-MS and used those data to calculate the number of
phosphate groups (Supplementary Materials, Table S1). Assuming that all OH groups of the secondary
face were phosphorylated, an average number of phosphate groups per OH of 2.55, 2.43, and 5.83 for
compounds 8, 9, and 10, respectively, was found, indicating that all ortho-, pyro-, and polyphosphate
species were most probably present as 31P NMR spectra previously suggested.
In a similar strategy, per(6-O-tert-butyldimethylsilyl)-β-CD 11 was used as starting material for
the attachment of methoxy poly(ethylene glycol) branches on the secondary rim of the macrocycle
and subsequent phosphorylation of the primary face (Scheme 2). Compound 11 was prepared by
reacting β-CD with TBDMSCl in pyridine as previously reported [49], although a new rapid and
reproducible purification method was developed. Thus, enough TBDMSCl was added in portions until
TLC (30:5:4 EtOAc–96% v/v EtOH–H2O) showed no undersilylated species (see Experimental part).
Purification of 11 was easily performed by a short flash chromatography using first the quaternary
mixture of solvents 40:40:20:4 CH2Cl2–MeCN–96% v/v EtOH–30% v/v aqueous NH3 to rapidly elute
the oversilylated byproducts, and then using 40:40:20:4 CH2Cl2–MeCN–96% v/v EtOH–H2O to quickly
wash out highly pure silyl 11 in 86% yield. Extensive propargylation and subsequent desilylation of
cyclooligosaccharide 11 according to published procedures [47] led to derivative 13, which in turn was
reacted with 1-azido-1-deoxy-ω-O-methoxypentatetraconta(ethylene glycol) 14 (average MW ~2000)
in the presence of CuBr as catalyst in DMF at 100 ◦C to give compound 15 in 57% yield after column
chromatography. 1H NMR spectrum of compound 15 showed two sharp peaks at δ 8.00 and 7.98 ppm
for the protons of the triazole rings located at C-2 and C-3 positions of the glucose residues of the
macrocycle, suggesting a C7 symmetry and, hence, the cycloaddition of fourteen PEG chains on the
secondary face of the β-CD. However, broad signals were found for the skeletal protons of the glucose
moieties, which can be reasoned in terms of macrocycle rigidity due to the high steric hindrance of
the molecule. The same effect was visible in the 13C NMR spectrum, with well-defined signals for
triazole rings but broad peaks for the glucose residues nuclei. Interestingly, the intense signals arising
from methylene groups of the fourteen long PEG chains dominated the dynamic range in both 1H
and 13C spectra. As a result, 13C satellite peaks could be observed as multiplets at δ 3.86–3.84 and
3.62–3.60 ppm in 1H NMR [55], as well as a set of sideband peaks symmetrically located at both sides
of the PEG signal (δ 69.6 ppm) at chemical shifts that were whole multiples of ~315 Hz in 13C NMR.
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3.2. MIL-100(Fe) nanoMOFs Synthesis and Surface Modification
MIL-100(Fe) nanoMOFs with a mean hydrodynamic diameter of 231 ± 14 nm and BET surface
area of 1690 ± 80 m2 g−1 were successfully synthesized by an organic solvent-free microwave-assisted
hydrothermal method [15]. Resulting nanoMOFs had typical facetted structures (Figure 1a) and
showed XRDP similar to those previously published (Supplementary Materials, Figure S24). Surface
modification of IL-100(Fe) nano OFs with PCDs was carried out through a “green” (meaning
organic solvent-free) method consisting of impregnation of nanoMOFs in aqueous solutions of
PCDs CD-P, 8–10 or 16 at different mass ratios nanoMOFs:PCDs, ranging from 100:1 to 3:1, to yield
nano OFs@PCD core-shell. Both uncoated and coated IL-100(Fe) nano OFs were characterized
by a set of complementary techniques. Even at the 3:1 nano OFs:PCDs mass ratio the particles
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maintained their facetted structures (Figure 1b–f). No morphological differences were found between
coated and uncoated particles, independently of the coating material. Indeed, XRDP studies indicated
that the crystalline structure of MIL-100(Fe) nanoMOFs was preserved after surface modification
(Supplementary Materials, Figure S24) in spite of the relatively high amounts of PCDs associated to
the nanoMOFs (see below). For instance, the strong reflections present in the uncoated sample were
preserved in the treated ones, showing that the integrity of the lattice was preserved in the latter,
which did however exhibit a supplementary flat background at wide angles and a stronger power-law
contribution at small angles, consistent with the presence of an additional amorphous component.
These observations are in agreement with previously reported data on different structures used as
coating for the same nanoMOFs [15,17]. The hydrodynamic diameters of MIL-100(Fe) nanoMOFs in
water were determined by DLS before and after surface modification. Measurements showed neither
mean size nor polydispersity significant variations after the coating process, independently of the
concentration and type of coating material. Mean diameters increased from 224 ± 21 nm for uncoated
nanoMOFs to 229 ± 18, 248 ± 25, 239 ± 17, 237 ± 19, and 241 ± 23 for nanoMOFs coated with CD-P,
8–10 and 16, respectively. These data indicated that the coating thickness was less than 15 nm in all
cases, and that no aggregation occurred. Similar behavior was found in DMEM biological medium
complemented with 10% FBS (Supplementary Materials, Figure S25). Again, no trace of aggregation
was observed as the mean diameters remained constant after 6 h incubation at 37 ◦C. These results
allow for biological studies on the interactions of coated nanoMOFs with macrophages.Nanomaterials 2019, 9, 1103 16 of 27 
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Figure 1. TEM images of nanosized metal-organic frameworks (nanoMOFs) before and after coating step:
(a) Uncoated nanoMOFs; (b) nanoMOFs@CD-P; (c) nanoMOFs@8; (d) nanoMOFs@9; (e) nanoMOFs@10;
(f) nanoMOFs@16. Scale bar: 200 nm.
The amount of PCDs associated with the nanoMOFs was determined by direct quantification
of the P content in the coated samples by ICP-MS after sample digestion, taking advantage of the
fact that P is the only element present in the PCDs derivatives but not in the nanoMOFs. As it can
be seen in Figure 2, the amount of PCDs attached to nanoMOFs was directly proportional to the
amount of the coating material employed for the nanoMOFs coating procedure. In parallel, the grafting
efficiencies of the various PCDs derivatives decreased from ~70 to ~35% with increasing the amount
of PCDs in the preparation procedure (Supplementary Materials, Figure S26). In the case of CD-P
and 8–10, the grafted amounts tended to reach a plateau when a 3:1 nanoMOFs:PCDs mass ratio was
used. Thus, CD-P and derivative 8 decorated with seven mannose residues directly attached to its
primary face reached a value of 10 ± 1 wt% of grafting, while PCD 10 coated the nanoMOFs in less
extension (9 ± 1 wt%). In contrast, PCD 9 decorated with seven flexible and less bulky TEG chains was
adsorbed onto the nanoMOF surface at 14 ± 1 wt%, suggesting that steric hindrance of the coating
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structure might correlate with the nanoMOFs covering density. However, PCD 16 having fourteen
long PEG chains on the secondary face showed the highest covering value of the series (16 ± 1 wt% at
a 3:1 nanoMOF:16 mass ratio). Nevertheless, the amounts of coating PCDs were in the same range
of previously reported values for other PCDs derivatives on the same MIL-100(Fe) nanoMOFs (~17
wt%) [17].
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Figure 2. Phosphate β-CD derivatives (PCDs) grafting (wt%) versus nanoMOFs:PCDs mass
ratio assayed.
Lack of colloidal stability is an important drawback hampering nanoparticle biomedical
applications. Zeta potential analysis gives values of the nanoparticles global charge, which depends
on pH, presence of ions, and nanoMOFs concentration. Measurements were performed at pH 7.4 and
reflect the stability of the syste . Results are depicted in Figure 3, which shows that the ZP values
shifted from −26 ± 1 mV for the uncoated nanoMOFs to values b tween −21 ± 1 and −18 ± 1 mV for the
nanoMOFs cove d with CDs CD-P and 8–10. However, when PCD 16 was used, oated n noMOFs
reached ZP values close to 0 (−4 ± 1 mV). This behavior is a clear i dication that the carboxylate
surface groups on the nanoMOFs were shielded by the nonionic PEG chains. These observations are in
agreement with previously reported ZP values close to zero in the case of other types of PEG-coated
nanoparticles [37].
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3.3. ITC Experiments on ConA Biorecognition
Mannose-coated MIL-100(Fe) nanoMOFs are the result of the self-assembly of multiple heptavalent
mannose clusters (8 and 10) on the surface of the nanoparticles. Displaying a multivalent presentation
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of mannoside ligands would be equivalent to an artificial “glycocalix” [40]. To test the molecular
recognition properties of such mannose-coated nanoMOFs, we studied the binding affinity of
glycoclusters 8 and 10, as well as mannose-coated nanoMOFs@8 and nanoMOFs@10, towards the
model mannose-specific lectin concanavalin A (ConA) by using isothermal titration calorimetry (ITC).
This technique allows the quantification of the stoichiometry, affinity, and thermodynamic profile for
the interaction between ligands and receptors by detecting the heat released or absorbed during the
binding event. Indeed, ITC directly provides values for the enthalpy change of binding (∆H), while
the binding constant (K) and the stoichiometry (n), defined as the ratio between the concentration of
the conjugates and the protein when the lectin binding sites are saturated, are estimated from the best
fit to a model of n equal and independent sites by a nonlinear least square algorithm. It is important to
highlight that the selected model lectin, ConA, and the actual human macrophage mannose receptor
(hMMR) are different, both at structural and binding mechanism levels, and thus, any extrapolation
from the former to the latter should be made with care. However, recently it has been reported
that affinities of a series of mimics for both lectins in solution are qualitatively similar [56,57], which
supports our choice.
Titration experiments for mannosylated PCDs 8 and 10 were performed in 20 mM phosphate buffer
at pH 7.2 at 25 ◦C. Aliquots of each PCD were injected into a solution of ConA within the calorimeter cell
and the amount of released heat following each injection was plotted against the molar ratio between
the conjugate and the lectin (Figure 4 and Figure S27). In addition, control experiments were performed
by injecting ligands into the cell containing buffer without lectin and showed insignificant heats of
dilution. Thermodynamic profiles calculated by fitting the obtained data to the model can be found in
Table 1 and Figure 5, and are in sharp agreement to those typically reported for protein-carbohydrate
binding [50,58]. Indeed, ITC experiments showed clearly exothermic interactions with ConA for both
conjugates 8 and 10. Thus, their thermograms were characterized by negative peaks corresponding to
a release of heat associated with the binding interaction, which diminished progressively due to the
gradual saturation of the protein binding sites. Thermogram for PCD 10 reached a plateau at lesser
concentration ratio than that for 8, which can be reasoned taking into account that the binding constant
for the former is 2.3-fold higher than that for the latter (Table 1). Both thermodynamic profiles were
very similar and enthalpy-driven (Figure 5), comprising favorable (negative) enthalpic terms partially
counterbalanced by smaller unfavorable (negative) entropic contributions.
Interestingly, binding enthalpy for conjugate 8 was slightly more favorable (~4%) than that for 10,
which may suggest a better docking of the mannose moieties of the former to the carbohydrate-binding
sites of the protein. However, entropic unfavorable term was ~17% larger in the case of 8, resulting in a
compensation of ~50% of the enthalpy contribution for this conjugate while 10 showed an entropic
counterbalance of only ~44%. This fact explains why the interaction was stronger in the case of
conjugate 10 as their respective binding constants reveal, and it was clearly related to the presence
of tetra(ethylene glycol) spacers between the mannose residues and the cyclooligosaccharide in its
structure. These tethers most probably increased the distance and mobility of the monosaccharides
around the primary face of the macrocycle, moderating the rigidity gain after protein binding and
thus softening the concomitant entropic lost. Previous reports have shown the beneficial effects of
introducing flexible and relatively long bridges between a β-CD core and sugar ligands on their ability
to bind lectins in solution [59,60]. Regarding the stoichiometry of the interactions, the ratios between the
concentration of the conjugates and the protein when the system reaches saturation (n) were calculated
as 2.44 and 2.79 for compounds 8 and 10, respectively (Table 1). ConA is well-known to present a
tetrameric structure at pH values above 7.0, with a unique mannose-binding site per monomer [61].
Thus, n values below 4 suggest that not all binding sites of the protein were occupied when the system
reached saturation, which might be reasoned in terms of crowded spatial arrangements taking into
account the sharp differences in sizes between the lectin and the mannose-containing phosphates 8
and 10.
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Table 1. Thermodynamics and stability constants for the binding of conjugates 8, 10, nanoMOFs@8,
and nanoMOFs@10 to ConA according to an n equal and independent binding sites model.
Conjugate N a K × 10−5 (M−1) ∆G0 (kcal mol−1) ∆H (kcal mol−1) T∆S0 (kcal mol−1)
8 b 2.44 ± 0.01 2.25 ± 0.08 −7.30 ± 0.02 −14.49 ± 0.06 −7.19
10 b 2.79 ± 0.01 5.12 ± 0.25 −7.79 ± 0.03 −13.96 ± 0.07 −6.17
nanoMOFs@8 c 0.90 ± 0.01 14.20 ± 1.64 −8.39 ± 0.07 −334.20 ± 6.91 −325.81
nanoMOFs@10 c 1.06 ± 0.01 24.50 ± 1.17 −8.72 ± 0.03 −314.10 ± 3.37 −305.38
a [conjugate]:[ConA] ratio when the lectin binding sites are fully saturated. Concentration of ConA was calculated
as tetramer; b 20 mM phosphate buffer (pH 7.2) at 25 ◦C; c 10 mM TRIS buffer (pH 7.5) at 25 ◦C.Nanom terials 2019, 9, 1103 18 of 27 
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Figure 4. Titration of concanavalin A (ConA) with conjugate 10 in 20 mM phosphate buffer (pH 7.2)
at 25 ◦C. The top panel shows the raw calorimetric data denoting the amount of generated (negative
exothermic peaks) heat following each injection of the conjugate. The area under each peak represents
the amount of heat released upon binding of the conjugate to the lectin. Note that as the titration
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data to the model of n equal and independent binding sites.
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In contrast to 8 and 10, ITC experiments with nanoMOFs@8 and nanoMOFs@10 were performed in
10 mM TRIS (pH 7.5) buffer due to the fact that phosphate buffer used above could compete for the iron
sites within the nanoparticles surface, causing the coating depletion. Furthermore, inverse titration was
required for nanoMOFs@8 and nanoMOFs@10 since colloidal stability for these nanoparticles had only
been tested at concentrations below 1 mg/mL (~21 and ~15 µM of coating PCDs 8 and 10, respectively,
on the nanoMOFs surface) which turned out to be too low when direct titrations were attempted.
Thus, in these cases aliquots of solutions of ConA lectin in concentration below its aggregation limit
(80 µM as tetramer, in our hands) were injected within nanoparticle colloidal suspensions contained
in the calorimeter cell. To the best of our knowledge, this was the first time that the interaction of
nanoMOFs coated with biorecognizable moieties towards their biological receptor counterpart was
evaluated by this technique. As previously discussed for free PCDs 8 and 10, obtained thermograms for
nanoMOFs@8 and nanoMOFs@10 were strongly exothermic, presenting negative peaks that become
shorter after each injection (Supplementary Materials, Figure S27). Again, fitting obtained data to the
model of n equal and independent binding sites gave us enthalpy-driven thermodynamic profiles for
both coated systems (Table 1 and Figure 5). Noticeably, binding enthalpies turned out to be ~23-fold
more favorable than those previously measured for the free coating agents 8 and 10, reaching values
more negative than −300 kcal mol−1. Similarly, unfavorable entropic terms were of the same order of
magnitude, compensating ~97% of the enthalpic contributions in both cases. Such behavior has also
been reported in the case of gold nanoparticles coated with sugars when interacting with ConA [62],
and it was most likely a consequence of the high density of ligands present on the nanoparticle surface
resulting in a remarkable multivalent effect. In absolute terms, calculated ∆G0 values were 12–15%
more favorable for the nanoparticles than those for the free phosphates, and thus the binding constants
for nanoMOFs@8 and nanoMOFs@10 were 6.33-fold and 4.8-fold larger, respectively. Once more,
the binding affinity of nanoMOFs@10 presenting TEG spacers was ~2-fold stronger than that for
nanoMOFs@8, where the mannose residues were directly attached to the primary face of the macrocycle,
most probably explained through the better fit of the ligand associated with the higher flexibility of the
linker, reducing the steric hindrance. Again, n values for nanoMOFs@8 and nanoMOFs@10 were below
4 when interacting with the lectin (0.90 and 1.06, respectively), suggesting an extensive covering of the
coated nanoparticles surface by protein tetramers at the system saturation point. This was possible due
to the fact that the nanoparticles showed an average diameter of 231 nm, which was ~29-fold larger
than the lectin, having a reported hydrodynamic diameter of ~8 nm [63].
Finally, it should be underlined that despite the sharp differences in the values of the
thermodynamic parameters calculated for 8, 10, nanoMOFs@8, and nanoMOFs@10, all evaluated
mannoside derivatives showed typical energetic profiles for protein-carbohydrate association
events [50,58]. Indeed, the enthalpy–entropy compensation was strongly linear with a slope of
~1.00 and a correlation coefficient of 1 (Supplementary Materials, Figure S28).
3.4. Interactions of Surface-Modified nanoMOFs with a Macrophage Cell Line
Once demonstrated by ITC that mannose-coated nanoMOFs recognized a specific protein receptor
with enhanced avidity, we evaluated the interactions of nanoMOFs coated with 8–10 and 16 with
macrophages on the murine macrophage cell line J774A.1. To compare the efficacy of different coatings,
an incubation time of 4 h was chosen. Indeed, for uncoated MIL-100(Fe) nanoMOFs, this time
corresponded to an efficient uptake by J774A.1 macrophages [64] as is in the order of magnitude of
blood circulation times of PEG-coated nanoparticles [20]. Quantitative measurement on the amounts
of nanoMOFs uptaken in cells were obtained by ICP-MS, after contact of nanoparticles with cells
followed by extensive washing to remove the nonassociated particles. As shown in Figure 6, around
75% of uncoated nanoMOFs were taken up in macrophages after 4 h incubation, corresponding to
around 23 µg nanoMOFs/3 × 105 cells. This result demonstrates that macrophages avidly take up
nanoMOFs, in agreement with reported data [64]. Remarkably, the presence of PCDs 8–10 or 16 on the
nanoparticles surface significantly reduced the nanoMOFs internalization. The nanoMOFs amounts
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uptaken by the cells decreased in the order CD-P > 8 > 16 > 10 > 9, with uptake percentages of 41 ± 3,
33 ± 5, 32 ± 2, 22 ± 2, and 21 ± 3%, respectively (Figure 6). These results indicated that all of the PCDs
coatings played a role on the nanoMOFs cell internalization, although the relationship between the
uptaking reduction and the structure is not obvious.
Nanomaterials 2019, 9, 1103 20 of 27 
 
suggesting an extensive covering of the coated nanoparticles surface by protein tetramers at the 
system saturation point. This was possible due to the fact that the nanoparticles showed an average 
diameter of 231 nm, which was ~29-fold larger than the lectin, having a reported hydrodynamic 
diameter of ~8 nm [63]. 
Finally, it should be underlined that despite the sharp differences in the values of the 
thermodynamic parameters calculated for 8, 10, nanoMOFs@8, and nanoMOFs@10, all evaluated 
mannoside derivatives showed typical energetic profiles for protein-carbohydrate association events 
[50,58]. Indeed, the enthalpy–entropy compensation was strongly linear with a slope of ~1.00 and a 
correlation coefficient of 1 (Supplementary Materials, Figure S28). 
3.4. Interactions of Surface-Modified nanoMOFs with a Macrophage Cell Line 
Once demonstrated by ITC that mannose-coated nanoMOFs recognized a specific protein 
receptor with enhanced avidity, we evaluated the interactions of nanoMOFs coated with 8–10 and 16 
with macrophages on the murine macrophage cell line J774A.1. To compare the efficacy of different 
coatings, an incubation time of 4 h was chosen. Indeed, for uncoated MIL-100(Fe) nanoMOFs, this 
time corresponded to an efficient uptake by J774A.1 macrophages [64] as is in the order of 
magnitude of blood circulation times of PEG-coated nanoparticles [20]. Quantitative measurement 
on the amounts of nanoMOFs uptaken in cells were obtained by ICP-MS, after contact of 
nanoparticles with cells followed by extensive washing to remove the nonassociated particles. As 
shown in Figure 6, around 75% of uncoated nanoMOFs were taken up in macrophages after 4 h 
incubation, corresponding to around 23 μg nanoMOFs/3 × 105 cells. This result demonstrates that 
macrophages avidly take up nanoMOFs, in agreement with reported data [64]. Remarkably, the 
presence of PCDs 8–10 or 16 on the nanoparticles surface significantly reduced the nanoMOFs 
internalization. The nanoMOFs am unts uptaken by the cells decreased in the order CD-P > 8 > 16 > 
10 > 9, with uptake percentages of 41 ± 3, 33 ± 5, 32 ± 2, 22 ± 2, and 21 ± 3%, respectively (Figure 6). 
These results indicated that all of the PCDs coatings played a role on the nanoMOFs cell 
internalization, although the relationship between the uptaking reduction and the structure is not 
obvious. 
 
Figure 6. In vitro interaction of uncoated and coated nanoMOFs with PCDs CD-P, 8–10, and 16 with 
a J774A.1 macrophage cell line. 50 μg/mL nanoMOFs were incubated with 3 × 105 J774A.1 cells for 4 
h, and then washed to remove the nonfirmly bound nanoMOFs. After cell lysis, the amount of 
internalized nanoMOFs was determined by ICP-MS and was expressed as a % of the initial amount 
put in contact with the cells. 
Interestingly, an almost two-fold reduction of internalization was observed for the nanoMOFs 
coated with CD-P without any further modification (from 75% for uncoated nanoMOFs to 41% for 
nanoMOFs coated with CD-P). This was a surprising result as to the best of our knowledge no study 
has reported yet that a CD coating could reduce macrophage uptake. When CD was further 
Figure 6. In vitro interaction of uncoated and coated nanoMOFs with PCDs CD-P, 8–10, and 16 with
a J774A.1 macrophage cell line. 50 µg/mL nanoMOFs were incubated with 3 × 105 J774A.1 cells for
4 h, and then washed to remove the nonfirmly bound nanoMOFs. After cell lysis, the amount of
internalized nanoMOFs was determined by ICP-MS and was expressed as a % of the initial amount put
in contact with the cells.
Interestingly, an almost two-fold reduction of internalization was observed for the nanoMOFs
coated with CD-P without any further modification (from 75% for uncoated anoMOFs to 41% for
nanoMOFs c ated with CD-P). This was a surprising result as to th best of our k owledge no s udy has
reported yet that a CD coating could reduce macrophage uptake. When CD was further functionalized
with PEG chains (16), which are well known to reduce macrophage uptake [65], a better “stealth”
effect was obtained with around 32% cell association compared to 41% for nanoMOFs coated with
CD-P. A similar effect was obtained in the case of PCD 8 (~33%), where mannose was attached to the
macrocycle instead of PEG chains. The most efficient “stealth” behavior was observed for nanoMOFs@9
and mannose-grafted nanoMOFs@10, both characterized by short TEG chain in the structure, showing
less than one third uptake as compared to uncoated nanoMOFs (from 75% for uncoated nanoMOFs
to 21% and 22% for nanoMOFs@9 and nanoMOFs@10, respectively). This result suggests that the
presence of short TEG chains optimizes the “stealth” effect with respect to longer PEG chains, which
are not able to decrease very significantly the cellular uptake with respect to plain CD-P. Possibly, part
of PEG chains might penetrate inside the nanoMOF pores, as previously reported [15]. Moreover, since
the MW of PEG-CD 16 is much higher than that of 8–10, and their coating efficiencies, which are based
on P content in the coated samples, are similar, it was expected that the MOF surface would be coated
with more molecules of 8–10 than molecules of 16, and therefore the PEG density might not have been
enough to promote a more efficient “stealth” effect.
In the cases of nanoMOFs@8 and nanoMOFs@10, mannose grafting did not increase nanoMOFs
uptake, as one would have expected. Macrophages internalize nanoparticles through different
mechanisms depending on the physicochemical properties of the nanomaterials, including particle size,
particle shape, surface charge, and surface modification with organic and/or biological molecules [66].
It is known that uncoated nanoMOFs uptake by J774A.1 macrophages is driven principally by
phagocytosis [64], a mechanism which is strongly influenced by the specific composition of the protein
corona [15,20,21]. “Stealth” effects of PEG coating on nanomaterials are not dependent on a reduction
of protein corona adsorption but on a change of the type of proteins adsorbed on the surface from the
blood plasma, more specifically to the binding of mainly clusterin protein [67]. Our results suggest that
when mannose-coated nanoMOF@8 and nanoMOF@10 are placed in a complex biological environment,
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the binding of clusterin to the surface of such nanoparticles not only contributes to an efficient
“stealth” effect, but also may shield the accessibility of the mannose ligands to their macrophage
surface specific receptors. Furthermore, mannose-vectorized nanomaterials towards macrophages are
dominantly internalized by energy-dependent clathrin-mediated endocytosis [68–70]. Such mechanism
is affected by the particle size and works well when particles are smaller than 200 nm [71]. Thus,
nanoMOFs@8 and nanoMOFs@10 uptake may also be hindered by the relatively large size of the
nanoparticles. These observations reflect the complexity of surface functionalization of highly porous
MIL-100(Fe) nanoMOFs.
3.5. DOX-Loaded MIL-100(Fe) nanoMOFs Surface Modification
Finally, we investigated the coating of anticancer drug DOX-loaded nanoMOF with TEGylated
PCD 9, since nanoMOF@9 displayed the most efficient “stealth” effect. DOX payload reached
17 ± 3 wt%, corresponding to a loading efficiency of 85 ± 2%. This good loading efficiency indicated
the strong interaction between DOX and MIL-100(Fe) nanoMOFs, in agreement with the previous
reports [72]. The drug-loaded nanoMOFs were further coated with 9, by the same one-step procedure
in water described above. The functionalized particles had similar diameters (235 ± 21 nm) to those
of the unloaded ones (226 ± 24 nm). Interestingly, surface modification of nanoMOFs with 9 did not
induce DOX release, showing less than 2 ± 0.4% DOX release after 12 h incubation with this PCD. The
coating of DOX-loaded nanoMOFs with targeting ligands and DOX release studies in cancer cells will
be the subject of further studies. These results showed that the coating strategy described herein can
be applied to nanoMOFs previously loaded with a drug.
4. Conclusions
In conclusion, we have developed a convenient method for the coating of nanoMOFs MIL-100(Fe)
with TEG, PEG, and mannose residues. The method consisted of the organic solvent-free self-assembly
on the nanoMOFs surface of building-blocks based on β-CD having functional moieties (TEG, PEG, and
mannose) on one face and multiple phosphate groups on the other side. The coating can also be applied
to doxorubicin-loaded nanoMOFs MIL-100(Fe) without significantly affecting the payload of the
nanoparticles. Mannose-coated nanoMOFs displayed a remarkable enhanced binding affinity towards
a specific mannose receptor such as Concanavalin A due to the so-called multivalent effect. However,
these remarkable mannose recognition properties were not translated into improved macrophage
uptake. By contrast, such mannosylated systems showed reduced macrophage internalization as
compared with uncoated nanoMOFs. Furthermore, our results showed that coating nanoMOFs
with cyclodextrin phosphate led to a significant “stealth” effect, slightly improved by PEGylated or
mannosylated cyclodextrin phosphate coating. More notable, the nanoMOFs surface modification with
TEGylated and mannosyl-TEGylated PCDs, having a much shorter oligoethylene chain, displayed
the most efficient “stealth” effect. These results highlight the complexity of the involved interactions,
particularly in a biological environment. Further research will be performed to comprehensively
understand the localization and functions of each cyclodextrin phosphate component as well as the
structural requirements to ensure molecular recognition properties in a biological medium. Our results
showed that PCDs offer a versatile platform to coat nanoMOFs in an organic solvent-free, one step
manner, and to impart biorecognition properties to nanoMOFs.
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Abbreviations
β-CD β-cyclodextrin
CD-P β-cyclodextrin phosphate sodium salt
ConA concanavalin A
DMAP 4-dimethylaminopyridine
DMEM Dulbecco’s modified Eagle’s medium
DMF dimethylformamide
DOX doxorubicin
EtOAc ethyl acetate
FBS fetal bovine serum
HR-ICP-MS high resolution inductively couples plasma mass spectrometry
ITC isothermal titration calorimetry
MALDI-TOF-MS matrix-assisted laser desorption/ionization time-of-flight mass spectrometry
MWCO molecular weight cut-off
NaAsc (+)-sodium l-ascorbate
nanoMOFs nanosized metal-organic frameworks
PCDs phosphorylated β-CD derivatives
PEG polyethylene glycol
TEG tetraethylene glycol
TEM transmission electron microscopy
TLC thin-layer chromatography
XRDP X-ray diffraction patterns
ZP zeta potential
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